Laurent leads Cukierman & Co. Life Sciences since 2008 and has been involved in more than 100 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture-backed and middle market companies for fund raising, licensing deals and M&A transactions as well as strategic projects for key life sciences industry players.

Laurent brings an extensive international life sciences experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, medical devices, biotechnology, nutraceuticals, animal health and direct-to-consumer markets.

After a veterinary practice and a new venture management experience, he worked 10 years in Schering-Plough (acquired by Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, General Manager in Israel and Vice President, Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE, dedicated to Alzheimer’s disease and AA amyloidosis).

Laurent is a board member of Israel Brain Technology (IBT) http://israelbrain.org/, HeroKi Ltd. www.heroki.co and N.E.W.S. Navigation www.newsnavigation.org.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3 and lives in Lausanne (Switzerland) and Tel Aviv (Israel).

Daniel has been involved with Cukierman & Co. Life Sciences since 2009 in various capabilities focusing Venture Capital & Strategy consulting. In the last 17 years, Daniel has been involved in more than 100 medtech and biotech transactions and consulting assignments.

Daniel serves as board member for several Israeli companies and support on regular basis most of the large Israeli life Sciences investors in Due Diligence and Strategy.

Daniel’s past experience includes Senior Investment Director at Fosun Pharma (close to $400M investment) from 2013 to 2016, Principal at Omnes Capital (fund of funds activity and co-investment) from 2010 – 2013 and Director at Market Bridges (rep office of JMP Securities) from 2004 – 2010. Daniel has a B.Sc in Computer Sciences and an MBA from ESSEC Business School in Paris. He is married, father of 3 and lives in Tel Aviv (Israel)

Laurence Blazianu is a healthcare professional with a successful track record in partnerships, fund raising, corporate marketing, and financial analytics addressing the needs from investors & business partners, with over 16 years of experience. Laurence worked in the management of a number of highly innovative start-up companies with Xeltis, Quantis, Kenta Biotech, Shogoo Pharma.

She started her career at Hoffmann-La Roche affiliates (US-UK) and Headquarters where she started in local sales & marketing, and then global marketing and partnering focusing on projects and companies’ valuation, deal structuring, and in-licensing/M&A activities. She moved then to Credit-Suisse Private Banking Headquarters as Analyst for global investments recommendations in the Pharma-Biotech-Medtech sectors.

Laurence is also an executive spoke person and a member of the Chartered Institute for Public Relations (UK). She graduated in international business administration from the French University (Annecy and Clermont-Ferrand), and in Business English from the University of California, San Diego. 

Alexandra joined Cukierman & Co. Life Sciences in 2009 and brings a comprehensive international experience in R&D, business development and corporate strategy.  From 2003 to 2009, she has carried out her PhD in Immunology/Virology at bioMérieux (France) and her post-doctorate at the Weizmann Institute of Science (Israel). She co-authored more than 15 peer-reviewed international publications and received 6 academic awards. From 2007 to 2012, she served as Associate Partner of Quilt Solutions, a Swiss company customizing business development and market access in Life Sciences. From 2009 to 2010, she served as VP Business Development and then as CEO of Recogene Ltd., a biotech start-up within RAD BioMed Accelerator (Israel), developing innovative systems in gene therapy. Since 2009, she serves as Executive VP Sciences and Executive Director Europe of the Signal Group, the leading provider of ecosystem intelligence solutions for Global 2000 corporate decision makers.

  Alexandra is a PhD in Immunology/Virology of the University Claude Bernard Lyon I (France) and earned an International MBA from Bar Ilan University (Israel).

Arnaud joined as Managing Partner of Cukierman & Co. New Mobility and Partner of Cukierman & Co. Life Sciences in October 2018. Arnaud has an extensive experience as investment banker with OSP Partners (Paris and New York), where he handled, as a partner, exclusive mandates for Siemens and Vivendi and more. He left to manage Ingersoll Engineers, an international consulting firm specialized in new product development and project management, that he sold to Orgaconseil (now Sopra Conseil), before moving from Paris to Israel where he lives today.

In Israel, he fulfilled a few dreams, like building a small luxurious hotel in the middle of the desert. He also managed Learni, an Edtech Israeli company and was among the first managers to join Space IL in charge of the organization. Arnaud is also one of three cofounders of Volleto, a leading CRM platform for luxury brands.

As a partner in Cukierman Group, he will be in charge of marketing exclusive life sciences companies toward family offices and non-specialized investors. Arnaud was the  youngest Maître de Conference then Professor at HEC Paris. He was also the Co-Founder of the Start Up Jury at Hec Paris and member of the jury of the design engineering department at L’Ecole des Mines de Paris. He holds a PhD degree from the Ehess in Paris.

 

Sephora joined Cukierman & Co. Life Sciences in 2015 after having moved from France to Israel and currently serves the company as an associate.

Before joining CLS, Sephora worked with ‘Hewlett Packard’ Israel as a financial analyst. As part of the financial department in charge of all the software sales where she developed her financial analytics skills. Sephora brings her extensive academic background in management, marketing and financial analytics.

Sephora graduated in 2015 and earned her M.Sc. from the international Business School ‘ Grenoble Ecole de Management’ (France).

Shy is a senior experienced executive in the Medical and Hi-tech industry, with over 25 years of Business Development, Sales and Management for high technology companies. Prior to joining Cukierman he has been the CEO of PerfAction Technologies, the global SVP sales for Viora Technologies and former CEO of 2 other start-up companies. Shy specialized in Asian markets and have been the co-founder of Yoki-Kal, a leading BD company for the Japanese and Asian markets consulting numerous companies as Motorola, IAI, Orbit, SHL, STI, CTS and more. Very familiar with the Medical Devices market, mainly the emerging Medical Aesthetics arena.  Studied Computer Science and Physics at the Technion Talented Youth program, Business Administration at TLV Business College & at the Wales University. Shy is also a retired Lieutenant Commander of the Israeli navy where he graduated the Naval Officers academy.

Julia Solomon joined Cukierman & Co Investment House in 2018.

Prior to joining Cukierman and Co. Life Sciences, Julia did an internship at Cukierman & Co. Technology, Media and Telecom. She was actively involved in the preparation and execution of many cross-border private placement and M&A transactions.

She worked in Paris as an analyst in a start-up called Faste, a luxury lifestyle concierge, to assist a fundraising of €3M.

Julia founded a non profit organization, named Ohr Torah for a school in Toulouse which suffered from a terrorist shooting attack in March 2012. Each year they raise money with the help of many artists from around the world.

Julia holds a BSc in Business Management from the Royal Holloway University of London.

 

Haggai Ravid, CEO

Mr. Haggi Ravid is the Managing partner of Cukierman & Co.'s Investment Banking activities. Mr. Ravid was engaged in over $1B transactions over the past years, pioneering transactions such as taking the first Croatian company public on AIM, and completing the sale of first Telecom Hungarian based Nasdaq listed company. Prior to joining Cukierman, Mr. Ravid was a partner at MBI, an Investment House which jointly with Israel Industrial and Development Bank, invested in Israeli technology companies.

Mr. Ravid sits on the board of Cukierman and a variety of technology companies. Mr. Ravid graduated Cum Laude from the Hebrew University and has a MBA from Rutgers University.‪‪ 

Jack joined Cukierman & Co Investment House in 2019. Prior to joining Cukierman and Co. Life Sciences, Jack worked as an Investment Manager at MCG Capital, a Hong Kong-based private fund focusing on blockchain, AI, cloud computing and other sectors. Before this, he worked as a translator in Britain-based Mergermarket Group (now rebranded as Acuris Group) and was responsible for translating documents, research reports, intelligence and analysis reports on cross-border deals. He holds BAs in English Language from Shanghai University and a second BAs in Economics from East China Normal University.